Cyclooxygenase and Neuroinflammation in Parkinson’s Disease Neurodegeneration

Cyclooxygenase (COX) expression in the brain is associated with pro-inflammatory activities, which are instrumental in neurodegenerative processes such as Parkinson’s disease (PD). It is discussed that drugs with the capacity to rescue dopaminergic neurons from microglia toxicity and neuroinflammatory processes may result in an amelioration of parkinsonian symptoms by delaying the onset or slowing progression. This article reviews the involvement of COX in neuroinflammation, specifically focussing at the role of selective COX-2 inhibition in neuroinflammation and neurodegeneration in Parkinson’s disease.

• Publication year

  2010

• Venue

  Current Neuropharmacology

• Publication date

  2010-02-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/157015910790909485PMID 20808546PMCID 2866462
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Potential Adverse Effects of Cyclooxygenase-2 Inhibition: Evidence from Animal Models of Inflammation

  2012cited by this paper
• [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?

  2010cited by this paper
• [11C]-DPA-713 and [18F]-DPA-714 as New PET Tracers for TSPO: A Comparison with [11C]-(R)-PK11195 in a Rat Model of Herpes Encephalitis

  2009cited by this paper
• Tracers for TSPO: A Comparison with ( 11 C)-(R)-PK11195 in a Rat Model of Herpes Encephalitis

  2009cited by this paper
• The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research.

  2009cited by this paper
• NSAID Use and the Risk of Parkinson’s Disease

  2009cited by this paper
• Decreased blood–brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA

  2008cited by this paper
• Cyclooxygenase-2 is involved in oxidative damage and alpha-synuclein accumulation in dopaminergic cells.

  2008cited by this paper
• Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study.

  2008cited by this paper
• Seizure-Induced Up-Regulation of P-Glycoprotein at the Blood-Brain Barrier through Glutamate and Cyclooxygenase-2 Signaling

  2008cited by this paper
• The high affinity peripheral benzodiazepine receptor ligand DAA1106 binds to activated and infected brain macrophages in areas of synaptic degeneration: implications for PET imaging of neuroinflammation in lentiviral encephalitis.

  2008cited by this paper
• Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study.

  2008cited by this paper
• Brain and whole-body imaging in nonhuman primates of [11C]PBR28, a promising PET radioligand for peripheral benzodiazepine receptors

  2008cited by this paper
• Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system

  2007cited by this paper
• 11C-DPA-713: A Novel Peripheral Benzodiazepine Receptor PET Ligand for In Vivo Imaging of Neuroinflammation

  2007cited by this paper
• Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease

  2007cited by this paper
• Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease

  2007cited by this paper
• In vivo imaging of brain lesions with [11C]CLINME, a new PET radioligand of peripheral benzodiazepine receptors

  2007cited by this paper
• Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease.

  2007cited by this paper
• Journal of Neuroinflammation BioMed Central

  2007cited by this paper
• Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits

  2007cited by this paper
• Cyclooxygenase-2 Does Not Contribute to Postischemic Production of Reactive Oxygen Species

  2007cited by this paper
• Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease

  2006cited by this paper
• In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease.

  2006cited by this paper
• Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: A case-control study

  2006cited by this paper
• Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor‐α

  2006cited by this paper
• Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease

  2006influential reference
• NSAID use and the risk of Parkinson's disease.

  2006cited by this paper
• Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease

  2006cited by this paper
• Dopaminergic neurotoxicity by 6‐OHDA and MPP+: Differential requirement for neuronal cyclooxygenase activity

  2005cited by this paper
• Microglial activation in chronic neurodegenerative diseases: roles of apoptotic neurons and chronic stimulation.

  2005cited by this paper
• MPP+‐induced COX‐2 activation and subsequent dopaminergic neurodegeneration

  2005cited by this paper
• Microglial activation and dopamine terminal loss in early Parkinson's disease

  2005cited by this paper
• Relative Thromboembolic Risks Associated with COX-2 Inhibitors

  2005cited by this paper
• Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease

  2005cited by this paper
• Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease

  2004cited by this paper
• Neuroprotective Function of the PGE2 EP2 Receptor in Cerebral Ischemia

  2004cited by this paper
• Atypical antiinflammatory activation of microglia induced by apoptotic neurons

  2004cited by this paper
• Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation.

  2004cited by this paper
• Cyclooxygenase‐2 (COX‐2) in Inflammatory and Degenerative Brain Diseases

  2004cited by this paper
• Deficits in spatial learning and synaptic plasticity induced by the rapid and competitive broad‐spectrum cyclooxygenase inhibitor ibuprofen are reversed by increasing endogenous brain‐derived neurotrophic factor

  2003cited by this paper
• Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration

  2003cited by this paper
• Pathogenic role of glial cells in Parkinson's disease

  2003cited by this paper
• Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice.

  2003cited by this paper
• COX-3: a splice variant of cyclooxygenase-1 in mouse neural tissue and cells.

  2003cited by this paper
• Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease.

  2003cited by this paper
• Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra.

  2002cited by this paper
• Post-training cyclooxygenase-2 (COX-2) inhibition impairs memory consolidation.

  2002cited by this paper
• COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression

  2002cited by this paper
• CXCR4-activated astrocyte glutamate release via TNFα: amplification by microglia triggers neurotoxicity

  2001cited by this paper
• 15-deoxy-delta12,14-prostaglandin J2, a specific ligand for peroxisome proliferator-activated receptor-gamma, induces neuronal apoptosis.

  2001cited by this paper
• Cyclooxygenases: structural, cellular, and molecular biology.

  2000cited by this paper
• Howard Henry Tooth (1856–1925)

  2000cited by this paper
• Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

  2000cited by this paper
• Cyclopentenone prostaglandins—new allies in the war on inflammation

  2000cited by this paper
• Pathoanatomy of Parkinson’s disease

  2000cited by this paper
• Cyclooxygenase-2 Contributes to Functional Hyperemia in Whisker-Barrel Cortex

  2000cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper
• Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2.

  2000cited by this paper
• Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs.

  1999cited by this paper
• The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease.

  1999cited by this paper
• Oxidative stress and the pathogenesis of Parkinson's disease

  1996cited by this paper
• COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex.

  1996cited by this paper
• Characterization of inducible cyclooxygenase in rat brain

  1995cited by this paper
• Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids.

  1993cited by this paper
• Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

  1988cited by this paper
• Current neuropharmacology.

  1962cited by this paper

• Macrophage-induced enteric neurodegeneration leads to motility impairment during gut inflammation

  2025influential citation
• Neurotoxicity of typical liquid crystal monomers in zebrafish: Disruption of neurotransmitter pathways and underlying mechanisms

  2025cites this paper
• Repurposing of Potential Curcumin Derivatives Against Cyclooxygenase-2 Using In Silico Methods and Its Implications in Neurological Disorders.

  2025cites this paper
• The Therapeutic Potential of Butyrate and Lauric Acid in Modulating Glial and Neuronal Activity in Alzheimer’s Disease

  2025cites this paper
• Design of Chirality-Controlled Ketorolac-Peptide Conjugates for Selective COX-2 Inhibition and Localized Drug Release.

  2025cites this paper
• Postmortem Fatty Acid Abnormalities in the Cerebellum of Patients with Essential Tremor

  2024cites this paper
• Zingiber officinale Roscoe extract improves nigrostriatal dopaminergic activity in rotenone-induced Parkinsonian mice: implication of COX-2/TNF-α/IL-6 and antioxidant enzyme crosstalk in the immunoinflammatory responses

  2024cites this paper
• Low-dose aspirin increases olfactory sensitivity in association with enhanced neurogenesis and reduced activity of AChE in the experimental aging mice

  2024cites this paper
• Interactions between Cytokines and the Pathogenesis of Prion Diseases: Insights and Implications

  2024cites this paper
• Microbiota-microglia crosstalk between Blautia producta and neuroinflammation of Parkinson's disease: A bench-to-bedside translational approach.

  2024cites this paper
• Neonatal brain inflammation enhances methamphetamine-induced reinstated behavioral sensitization in adult rats analyzed with explainable machine learning.

  2024cites this paper
• Glutathione S-transferase: A keystone in Parkinson's disease pathogenesis and therapy.

  2024cites this paper
• Ferulic acid mitigated rotenone toxicity -Evoked Parkinson in rat model by featuring apoptosis, oxidative stress, and neuroinflammation signaling.

  2024cites this paper
• Acyclic sesquiterpenes nerolidol and farnesol: mechanistic insights into their neuroprotective potential

  2024cites this paper
• Exploring neuroglial signaling: diversity of molecules implicated in microglia-to-astrocyte neuroimmune communication

  2024cites this paper
• Pioglitazone ameliorates DOX-induced cognitive impairment by mitigating inflammation, oxidative stress, and apoptosis of hippocampal neurons in rats.

  2023cites this paper
• TonEBP Haploinsufficiency Attenuates Microglial Activation and Memory Deficits in Middle-Aged and Amyloid β Oligomer-Treated Mice

  2023cites this paper
• Plasma oxylipin profiles reflect Parkinson's disease stage.

  2023cites this paper
• Neuroprotective potential of formononetin, a naturally occurring isoflavone phytoestrogen

  2023cites this paper
• Oxytocin as neuro-hormone and neuro-regulator exert neuroprotective properties: A mechanistic graphical review.

  2023cites this paper
• Role of piRNA biogenesis and its neuronal function in the development of neurodegenerative diseases

  2023cites this paper
• Priming mesenchymal stromal cells with neurotrophic factors boosts the neuro-regenerative potential of their secretome.

  2023cites this paper
• Protective effects of Auranofin on the 6-hydroxydopamine model of Parkinson's disease in rats

  2023cites this paper
• Decoy Receptors Regulation by Resveratrol in Lipopolysaccharide-Activated Microglia

  2023cites this paper
• In Vivo Dopamine Neuron Imaging-Based Small Molecule Screen Identifies Novel Neuroprotective Compounds and Targets

  2022cites this paper
• Positional scanning of natural product hispidol’s ring-B: discovery of highly selective human monoamine oxidase-B inhibitor analogues downregulating neuroinflammation for management of neurodegenerative diseases

  2022cites this paper
• Neuron–Microglia Contacts Govern the PGE2 Tolerance through TLR4-Mediated de Novo Protein Synthesis

  2022cites this paper
• Cyclin-Dependent Kinase 5 Regulates cPLA2 Activity and Neuroinflammation in Parkinson’s Disease

  2022cites this paper
• Effect of citronellol on oxidative stress, neuroinflammation and autophagy pathways in an in vivo model of Parkinson's disease

  2022cites this paper
• Timapiprant, a prostaglandin D2 receptor antagonist, ameliorates pathology in a rat Alzheimer’s model

  2022cites this paper
• The Protein-Rich Fraction from Spirulina platensis Exerts Neuroprotection in Hemiparkinsonian Rats by Decreasing Brain Inflammatory-Related Enzymes and Glial Fibrillary Acidic Protein Expressions

  2022cites this paper
• Fluorine-18 Labelled Radioligands for PET Imaging of Cyclooxygenase-2

  2022cites this paper
• Prostaglandin D2 pathway in a transgenic rat model of Alzheimer’s disease: therapeutic potential of timapiprant a DP2 antagonist

  2022cites this paper
• Mechanistic roles for altered O-GlcNAcylation in neurodegenerative disorders.

  2021cites this paper
• Possible Link between SARS-CoV-2 Infection and Parkinson’s Disease: The Role of Toll-Like Receptor 4

  2021cites this paper
• Neuroprotective Effects of Neuropeptide Y against Neurodegenerative 
Disease

  2021cites this paper
• Immunotherapy – A Novel Facet of Modern Therapeutics

  2021cites this paper
• Progress in PET Imaging of Neuroinflammation Targeting COX-2 Enzyme

  2021cites this paper
• Design and synthesis of new 1,4,5-trisubstituted triazole-bearing benzenesulphonamide moiety as selective COX-2 inhibitors

  2021cites this paper
• Permeability of Hypogymnia physodes Extract Component—Physodic Acid through the Blood–Brain Barrier as an Important Argument for Its Anticancer and Neuroprotective Activity within the Central Nervous System

  2021cites this paper
• Mechanistic insights into the protective effect of paracetamol against rotenone-induced Parkinson's disease in rats: Possible role of endocannabinoid system modulation.

  2021cites this paper
• Aspirin as a Potential Geroprotector: Experimental Data and Clinical Evidence.

  2021cites this paper
• Protection of 6-OHDA neurotoxicity by PGF2α through FP-ERK-Nrf2 signaling in SH-SY5Y cells.

  2021cites this paper
• Bioactive lipids and their metabolism: New therapeutic opportunities for Parkinson's disease

  2021cites this paper
• NRM 2021 Abstract Booklet

  2021cites this paper
• CDK5 mediated phosphorylation of cytosolic phospholipase A2 regulates its activity and neuroinflammation in Parkinson’s Disease

  2021cites this paper
• Long Noncoding RNA SNHG1 Promotes Lipopolysaccharide-Induced Activation and Inflammation in Microglia via Targeting miR-181b

  2021cites this paper
• The inhibitory effects of Orengedokuto on inducible PGE2 production in BV-2 microglial cells

  2021cites this paper
• University of Groningen Is cyclooxygenase-1 involved in neuroinflammation ?

  2021cites this paper
• Is cyclooxygenase‐1 involved in neuroinflammation?

  2021cites this paper
• Neuroinflammatory responses in Parkinson’s disease: relevance of Ibuprofen in therapeutics

  2020cites this paper
• Protective effect of sodium propionate in Aβ1-42 -induced neurotoxicity and spinal cord trauma.

  2020cites this paper
• Fucoxanthin attenuates behavior deficits and neuroinflammatory response in 1-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine-induced Parkinson's disease in mice

  2020cites this paper
• Lead (Pb) as a Factor Initiating and Potentiating Inflammation in Human THP-1 Macrophages

  2020cites this paper
• 3,6’-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation

  2020cites this paper
• Molecular insights into benzene sulphonamide substituted diarylpyrazoles as cyclooxygenase-2 inhibitor and its structural modifications

  2020cites this paper
• PET Imaging of Cyclooxygenases in Neuroinflammation

  2020cites this paper
• Exploring the molecular approach of COX and LOX in Alzheimer’s and Parkinson’s disorder

  2020influential citation
• Immunotherapy in Neurodegenerative Disorders

  2020cites this paper
• The Effects of Celecoxib on Rotenone-Induced Rat Model of Parkinson’s Disease: Suppression of Neuroinflammation and Oxidative Stress-Mediated Apoptosis

  2019cites this paper
• The Protective Effect of Celecoxib on CA1 Hippocampal Neurons and Oxidative Stress in a Rat Model of Parkinson’s Disease

  2019cites this paper
• Distinct influence of COX‐1 and COX‐2 on neuroinflammatory response and associated cognitive deficits during high altitude hypoxia

  2019cites this paper
• Therapeutic implications of anti-inflammatory natural products in Alzheimer’s disease

  2019cites this paper
• Antioxidant, Anti-inflammatory, and Neuroprotective Effects of Novel Vinyl Sulfonate Compounds as Nrf2 Activator.

  2019cites this paper
• The Role of Lipids in Parkinson’s Disease

  2019cites this paper
• Gut Inflammation in Association With Pathogenesis of Parkinson’s Disease

  2019cites this paper
• PM2.5 exposure stimulates COX-2-mediated excitatory synaptic transmission via ROS-NF-κB pathway.

  2018cites this paper
• 2-Pentadecyl-2-Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease

  2018cites this paper
• Modulating Microglial Activation As a Possible Therapeutic Target for Depression

  2018cites this paper
• Insights into the Cyclooxygenase Pathway in a Progressive Rat Model of Parkinson’s Disease Induced by Prostaglandin J2: Protection with Ibuprofen

  2018cites this paper
• Inhibition of Cyclooxygenase-2 (COX-2) Initiates Autophagy and Potentiates MPTP-Induced Autophagic Cell Death of Human Neuroblastoma Cells, SH-SY5Y: an Inside in the Pathology of Parkinson’s Disease

  2018cites this paper
• Systemic Lipopolysaccharide-Induced Pain Sensitivity and Spinal Inflammation Were Reduced by Minocycline in Neonatal Rats

  2018cites this paper
• Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets

  2018cites this paper
• Ibuprofen Protects from Cypermethrin-Induced Changes in the Striatal Dendritic Length and Spine Density

  2018cites this paper
• Indomethacin promotes survival of new neurons in the adult murine hippocampus accompanied by anti-inflammatory effects following MPTP-induced dopamine depletion

  2018cites this paper
• Analgesic and anti-inflammatory properties of synthesized imidazopyrinidyl-chalcones: Relationship activity and structure

  2018cites this paper
• Regulatory Effects of Neuroinflammatory Responses Through Brain-Derived Neurotrophic Factor Signaling in Microglial Cells

  2018cites this paper
• YAKLAŞIMLAR NEUROINFLAMMATION MODIFYING APPROACHES IN PARKINSON ’ S DISEASE

  2018cites this paper
• Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments

  2017cites this paper
• Neuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson's disease.

  2017cites this paper
• Neuroprotective Activities of Spirulina platensis in the 6-OHDA Model of Parkinson’s Disease Are Related to Its Anti-Inflammatory Effects

  2017cites this paper
• Ligand-free, palladacycle-facilitated Suzuki coupling of hindered 2-arylbenzothiazole derivatives yields potent and selective COX-2 inhibitors.

  2017cites this paper
• Cyclooxygenase-2 Directs Microglial Activation-Mediated Inflammation and Oxidative Stress Leading to Intrinsic Apoptosis in Zn-Induced Parkinsonism

  2017cites this paper
• Aging and Neurological Diseases

  2017cites this paper
• Prostaglandin J2: a potential target for halting inflammation‐induced neurodegeneration

  2016cites this paper
• Therapeutic targets for Alzheimer's disease: Insights from in vitro and in vivo models of inflammation

  2016cites this paper
• Mechanisms by Which 17β-Estradiol (E2) Suppress Neuronal cox-2 Gene Expression

  2016cites this paper
• Does Diclofenac improve cognition and daily living functioning in Parkinson patients?

  2015cites this paper
• OPTIMISING DRUG DELIVERY : THE CHALLENGES AND OPPORTUNITIES “ New insights

  2015cites this paper
• Pentoxifylline Neuroprotective Effects Are Possibly Related to Its Anti-Inflammatory and TNF-Alpha Inhibitory Properties, in the 6-OHDA Model of Parkinson's Disease

  2015cites this paper
• Neuroinflammation and J2 prostaglandins: linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration

  2015cites this paper
• Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.

  2015influential citation
• Cobalt Protoporphyrin Upregulates Cyclooxygenase-2 Expression Through a Heme Oxygenase-Independent Mechanism

  2015cites this paper
• Alteration in Nuclear Factor-KappaB Pathway and Functionality of Estrogen via Receptors Promote Neuroinflammation in Frontal Cortex after 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Treatment

  2015cites this paper
• PACAP27 prevents Parkinson-like neuronal loss and motor deficits but not microglia activation induced by prostaglandin J2.

  2014cites this paper
• Parkinson-like neuronal loss and motor de fi cits but not microglia activation induced by prostaglandin J 2

  2014cites this paper
• Potent, orally available, selective COX-2 inhibitors based on 2-imidazoline core.

  2014cites this paper
• Neonatal exposure to lipopolysaccharide enhances accumulation of α-synuclein aggregation and dopamine transporter protein expression in the substantia nigra in responses to rotenone challenge in later life.

  2013cites this paper
• Celecoxib attenuates systemic lipopolysaccharide-induced brain inflammation and white matter injury in the neonatal rats.

  2013influential citation
• 1,4-Diaryl-substituted triazoles as cyclooxygenase-2 inhibitors: Synthesis, biological evaluation and molecular modeling studies.

  2013cites this paper